Requirements for Quantitative Analysis of Intimal Reaction in Arteries Treated with Intraluminal Stents

Journal of Endovascular Therapy

Volumn 10, Issue 6, 2003, Pages 1110-1116

  Uurto, Ilkka ^a   Juuti, Hanne ^b   Parkkinen, Jyrki ^a   Kellomäki, Minna ^b   Keski Nisula, Leo ^a   Nevalainen, Timo ^c   Törmälä, Pertti ^b   Salenius, Juha Pekka ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Angioplasty; Biodegradable stent; Canine model; Elastic lamina thickness; Experimental study; Histopathology; Intimal hyperplasia; Luminal diameter; Restenosis; Wallstent

Indexed keywords

STAINLESS STEEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA; ARTICLE; CONTROLLED STUDY; DOG; ILIAC ARTERY; MALE; MEASUREMENT; MORPHOMETRICS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RELIABILITY; RESTENOSIS; STENT;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIOPSY, NEEDLE; BLOOD VESSEL PROSTHESIS IMPLANTATION; DISEASE MODELS, ANIMAL; DOGS; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; PROBABILITY; PROSTHESIS DESIGN; SENSITIVITY AND SPECIFICITY; STENTS; TUNICA INTIMA;

EID: 1642535328     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/1545-1550(2003)010<1110:RFQAOI>2.0.CO;2     Document Type: Article

References (32)

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
2. Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-2980.
3. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489-495.
4. Ajani AE, Kim HS, Waksman R. Clinical trials of vascular brachytherapy for in-stent restenosis: update. Cardiovasc Radiat Med. 2001;2:107-113.
5. Williams DO. Intracoronary brachytherapy: past, present, and future. Circulation. 2002;105:2699-2700.
6. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part II. Circulation. 2002;106:2859-2866.
7. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part I. Circulation. 2002;106:2734-2740.
8. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
9. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation. 2002;105:1883-1886.
10. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002;106:2649-2651.
11. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697.
12. Isotalo T, Talja M, Tammela TL, et al. Cytotoxicity testing of a new caprolactone-coated self-expanding bioabsorbable self-reinforced poly-L-lactic acid urethral stent. Urol Res. 1999;27:149-152.
13. Isotalo T, Alarakkola E, Talja M, et al. Biocompatibility testing of a new bioabsorbable X-ray positive SR-PLA 96/4 urethral stent. J Urol. 1999;162:1764-1767.
14. Hietala EM, Salminen US, Stahls A, et al. Biodegradation of the copolymeric polylactide stent. Long-term follow-up in a rabbit aorta model. J Vasc Res. 2001;38:361-369.
15. Tamai H, Igaki K, Tsuji T, et al. A biodegradable poly-L-lactic acid coronary stent in porcine coronary artery. J Interv Cardiol. 1999;12:443-450.
16. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation. 2000;102:399-404.
17. Isotalo T, Talja M, Hellstrom P, et al. A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia. BJU Int. 2001;88:30-34.
18. Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106:1867-1873.
19. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-274.
20. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224-230.
21. Mathieu O, Cruz-Orive LM, Hoppeler H, et al. Measuring error and sampling variation in stereology: comparison of the efficiency of various methods for planar image analysis. J Microsc. 1981;121:75-88.
22. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol. 2000;190:300-309.
23. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 2002;106:798-803.
24. Regar E, Serruys PW, Bode C, et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002;106:1949-1956.
25. Farb A, John M, Acampado E, et al. Oral everolimus inhibits in-stent neointimal growth. Circulation. 2002;106:2379-2384.
26. Lincoff AM, Furst JG, Ellis SG, et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol. 1997;29:808-816.
27. Alt E, Haehnel I, Beilharz C, et al. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation. 2000;101:1453-1458.
28. De Scheerder I, Wang K, Wilczek K, et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation. 1997;95:1549-1553.
29. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol. 1998;32:780-786.
30. Yamagishi M, Hosokawa H, Saito S, et al. Coronary disease morphology and distribution determined by quantitative angiography and intravascular ultrasound-reevaluation in a cooperative multicenter intravascular ultrasound study (COMIUS). Circ J. 2002;66:735-740.
31. Prati F, Pawlowski T, Sommariva L, et al. Intravascular ultrasound and quantitative coronary angiography assessment of late in-stent restenosis: in vivo human correlation and methodological implications. Catheter Cardiovasc Interv. 2002;57:155-160.
32. Strehblow C, Gyongyosi M, Sperker W, et al. Usefulness of intravascular ultrasound-guided histological measurements after stenting in porcine coronary artery. Coron Artery Dis. 2002;13:291-294.